Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20979057rdf:typepubmed:Citationlld:pubmed
pubmed-article:20979057lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:20979057lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:20979057lifeskim:mentionsumls-concept:C0694888lld:lifeskim
pubmed-article:20979057lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:20979057lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:20979057lifeskim:mentionsumls-concept:C0065254lld:lifeskim
pubmed-article:20979057pubmed:issue1lld:pubmed
pubmed-article:20979057pubmed:dateCreated2011-1-21lld:pubmed
pubmed-article:20979057pubmed:abstractTextLiver tumor-initiating cells (T-ICs) are capable of self-renewal and tumor initiation and are more chemoresistant to chemotherapeutic drugs. The current therapeutic strategies for targeting stem cell self-renewal pathways therefore represent rational approaches for cancer prevention and treatment. In the present study, we found that Lup-20(29)-en-3?-ol (lupeol), a triterpene found in fruits and vegetables, inhibited the self-renewal ability of liver T-ICs present in both hepatocellular carcinoma (HCC) cell lines and clinical HCC samples, as reflected by hepatosphere formation. Furthermore, lupeol inhibited in vivo tumorigenicity in nude mice and down-regulated CD133 expression, which was previously shown to be a T-IC marker for HCC. In addition, lupeol sensitized HCC cells to chemotherapeutic agents through the phosphatase and tensin homolog (PTEN)-Akt-ABCG2 pathway. PTEN plays a crucial role in the self-renewal and chemoresistance of liver T-ICs; down-regulation of PTEN by a lentiviral-based approach reversed the effect of lupeol on liver T-ICs. Using an in vivo chemoresistant HCC tumor model, lupeol dramatically decreased the tumor volumes of MHCC-LM3 HCC cell line-derived xenografts, and the effect was equivalent to that of combined cisplatin and doxorubicin treatment. Lupeol exerted a synergistic effect without any adverse effects on body weight when combined with chemotherapeutic drugs. CONCLUSION: Our results suggest that lupeol may be an effective dietary phytochemical that targets liver T-ICs.lld:pubmed
pubmed-article:20979057pubmed:languageenglld:pubmed
pubmed-article:20979057pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:citationSubsetIMlld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20979057pubmed:statusMEDLINElld:pubmed
pubmed-article:20979057pubmed:monthJanlld:pubmed
pubmed-article:20979057pubmed:issn1527-3350lld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:MaStephanieSlld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:TangKwan HoKHlld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:LeeTerence...lld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:CastilhoAnton...lld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:NgIrene Oi...lld:pubmed
pubmed-article:20979057pubmed:authorpubmed-author:CheungVincent...lld:pubmed
pubmed-article:20979057pubmed:copyrightInfoCopyright © 2010 American Association for the Study of Liver Diseases.lld:pubmed
pubmed-article:20979057pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20979057pubmed:volume53lld:pubmed
pubmed-article:20979057pubmed:ownerNLMlld:pubmed
pubmed-article:20979057pubmed:authorsCompleteYlld:pubmed
pubmed-article:20979057pubmed:pagination160-70lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:meshHeadingpubmed-meshheading:20979057...lld:pubmed
pubmed-article:20979057pubmed:year2011lld:pubmed
pubmed-article:20979057pubmed:articleTitleLupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation.lld:pubmed
pubmed-article:20979057pubmed:affiliationState Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.lld:pubmed
pubmed-article:20979057pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20979057pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed